pursuant

<!-- Name:DistributionId Value:1000781880 --> <!-- Name:NewsArchiveTags Value:9014 --> <!-- Name:NewsArchiveOrgTags…

<!-- Name:DistributionId Value:1000780297 --> <!-- Name:NewsArchiveTags Value:9014 --> <!-- Name:NewsArchiveOrgTags…

<!-- Name:DistributionId Value:1000780320 --> <!-- Name:NewsArchiveTags Value:9014 --> <!-- Name:NewsArchiveOrgTags…

Pivotal Phase III IMbrave050 study investigating Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free survivalNew adjuvant…

NEW YORK--(BUSINESS WIRE)--$VOYA--On Dec. 29, 2022, Voya Financial, Inc. (NYSE: VOYA) paid a quarterly dividend of $0.20 per share on its common stock, par value $0.01 per share (“Common Stock”). As a consequence, the exercise price of the…

CUSIP #: 245915103 PHILADELPHIA--(BUSINESS WIRE)--On December 30, 2022, Delaware Investments Dividend and Income Fund, Inc. (NYSE: DDF) (the “Fund”), a closed-end fund, paid a monthly distribution on its common stock of $0.0551 per share…

Board of Directors Basel, 12 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that at its December meeting, the Board of Directors of Roche Holding Ltd has approved to propose the following changes at the Annual…

Phase III GRADUATE studies did not meet their primary endpoints of slowing clinical decline in people with early Alzheimer’sThe level of beta-amyloid removal by gantenerumab was lower than expected Topline data will be presented at the…